Glycopyrronium bromide/formoterol

Last updated

Glycopyrronium bromide/formoterol
Combination of
Glycopyrronium bromide Muscarinic anticholinergic
Formoterol Long-acting β2 agonist (LABA)
Clinical data
Trade names Bevespi Aerosphere
AHFS/Drugs.com Monograph
License data
Routes of
administration 		By mouth (inhalation)
ATC code
Legal status
Legal status
Identifiers
KEGG

Glycopyrronium bromide/formoterol, sold under the brand name Bevespi Aerosphere, is a combination medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [2] [3] It is a combination of glycopyrronium bromide and formoterol. It is inhaled. [2] [3]

Contents

The most common side effects include headache, nausea (feeling sick), muscle spasms and dizziness. [3]

Glycopyrronium bromide is a muscarinic receptor antagonist. [3] This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs. [3] Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open. [3]

Formoterol is a long-acting beta-2 agonist. [3] It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways. [3] When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open. [3]

Medical uses

Glycopyrronium bromide/formoterol is indicated as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). [3]

History

Glycopyrronium bromide/formoterol was approved for medical use in the United States in April 2016, [4] and in the European Union in December 2018. [3]

It is marketed by AstraZeneca. [2] [3]

References

  1. ↑ "Regulatory Decision Summary for Bevespi Aerosphere". 23 October 2014.
  2. 1 2 3 4 "Bevespi Aerosphere- glycopyrrolate and formoterol fumarate aerosol, metered". DailyMed. 29 May 2019. Retrieved 8 May 2020.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Bevespi Aerosphere EPAR". European Medicines Agency (EMA). 18 October 2018. Retrieved 8 May 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  4. ↑ "Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) Inhalation Aerosol". U.S. Food and Drug Administration (FDA). 16 February 2018. Archived from the original on 28 March 2021. Retrieved 8 May 2020.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.